Similar articles

• Effect of islet-activating protein (IAP) upon insulin secretion from human pancreatic islets.

  Araki Y, Yoshida T, Nakamura N, Koyama K, Nakamura Y, Nakano K, Kondo M. Araki Y, et al. Endocrinol Jpn. 1981 Apr;28(2):139-43. doi: 10.1507/endocrj1954.28.139. Endocrinol Jpn. 1981. PMID: 7030721
• Islet-activating protein (IAP)-induced adrenergic modulation of pancreatic A and B cell in dogs.

  Nakamura N, Yoshida T, Nakamura Y, Araki Y, Nakano K, Kanatsuna T, Kondo M. Nakamura N, et al. Horm Metab Res. 1984 Mar;16(3):128-31. doi: 10.1055/s-2007-1014718. Horm Metab Res. 1984. PMID: 6370819
• Glucagon suppression improves glucoregulation in moderate but not chronic severe diabetes.

  Lickley HL, Kemmer FW, Doi K, Vranic M. Lickley HL, et al. Am J Physiol. 1983 Oct;245(4):E424-9. doi: 10.1152/ajpendo.1983.245.4.E424. Am J Physiol. 1983. PMID: 6137957
• Purified islet cells in diabetes research.

  Pipeleers D. Pipeleers D. Horm Res. 1986;23(4):225-34. doi: 10.1159/000180328. Horm Res. 1986. PMID: 2870975 Review. No abstract available.
• Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes.

  Weir GC, Leahy JL, Bonner-Weir S. Weir GC, et al. Diabetes Metab Rev. 1986;2(1-2):125-61. doi: 10.1002/dmr.5610020108. Diabetes Metab Rev. 1986. PMID: 2424696 Review. No abstract available.